tradingkey.logo

tradingkey.logo
怜玢


COSCIENS Biopharma Inc

CSCI
りォッチリストに远加
2.720USD
0.0000.00%
終倀 05/15, 16:00ET15分遅れの株䟡
8.64M時䟡総額
損倱額盎近12ヶ月PER


詳现情報 COSCIENS Biopharma Inc 䌁業名

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

COSCIENS Biopharma Incの䌁業情報


䌁業コヌドCSCI
䌚瀟名COSCIENS Biopharma Inc
䞊堎日Dec 19, 1995
最高経営責任者「CEO」Ms. Anna Biehn
埓業員数- -
蚌刞皮類Ordinary Share
決算期末Dec 19
本瀟所圚地C/O Norton Rose Fulbright Canada Llp
郜垂TORONTO
蚌刞取匕所The Toronto Stock Exchange
囜Canada
郵䟿番号M5K 1E7
電話番号18439003201
りェブサむトhttps://www.cosciensbio.com/
䌁業コヌドCSCI
䞊堎日Dec 19, 1995
最高経営責任者「CEO」Ms. Anna Biehn

COSCIENS Biopharma Incの経営陣


䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
䌚瀟名
䌚瀟名/ポゞション
ポゞション
株匏保有
倉動額
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--

収益内蚳

通貚: USD曎新時刻: Apr 6, 2025
通貚: USD曎新時刻: Apr 6, 2025
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
䌚瀟から関連デヌタがただ開瀺されおいたせん。
地域別USD
䌚瀟名
収益
比率
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
事業別
地域別
䌚瀟から関連デヌタがただ開瀺されおいたせん。

株䞻

曎新時刻: Fri, Apr 17
曎新時刻: Fri, Apr 17
株䞻統蚈
皮類
株䞻統蚈
株䞻統蚈
比率
Goodwood Inc.
8.08%
Puccetti (Peter H)
0.49%
Kosciessa (Ulrich)
0.06%
他の
91.37%
株䞻統蚈
株䞻統蚈
比率
Goodwood Inc.
8.08%
Puccetti (Peter H)
0.49%
Kosciessa (Ulrich)
0.06%
他の
91.37%
皮類
株䞻統蚈
比率
Investment Advisor/Hedge Fund
8.08%
Individual Investor
0.55%
他の
91.37%

機関投資家保有株


曎新時刻: Wed, Apr 1
曎新時刻: Wed, Apr 1
報告期間
機関投資家数
保有株匏数
比率
倉動額
2026Q1
31
257.26K
8.08%
-38.43K
2025Q4
31
257.31K
8.08%
-38.39K
2025Q3
32
283.56K
8.74%
-15.54K
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
詳现を芋る

株䞻動向


䌚瀟名
保有株匏数
比率
倉動額
倉動率
日付
Goodwood Inc.
257.26K
8.08%
--
--
Jun 03, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
Planning Capital Management Corp
2.00
0%
--
--
Sep 30, 2024
RBC Dominion Securities, Inc.
--
0%
-4.24K
-100.00%
Sep 30, 2025
BNP Paribas Securities Corp. North America
--
0%
-100.00
-100.00%
Sep 30, 2025
Tower Research Capital LLC
--
0%
-38.00
-100.00%
Mar 31, 2025
詳现を芋る

関連ETF


銘柄名
比率
デヌタなし

配圓金


過去5幎間の配圓金総支払額は 0.00 米ドルである。
日付
配圓金
暩利確定日
支払日
配圓萜ち日
デヌタなし

株匏分割


日付
配圓萜ち日
皮類
比率
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
日付
配圓萜ち日
皮類
比率
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
KeyAI
î™